Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Ping Ge

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Theranostics|October 12, 2020
SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancerXi-Yu Liu, Wang Jiang, Ding Ma, et al.
Nature Communications|July 4, 2026
ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibitionLi-Ping Ge, Yu-Ling Xiao, Song-Yang Wu, et al.
Journal of Pharmacological Sciences|April 9, 2020
Finding a resveratrol analogue as potential anticancer agent with apoptosis and cycle arrestZhen-Hui Xin, Hui-Hui Yang, Yu-Han Gan, et al.
Breast Cancer (Dove Medical Press)|December 11, 2024
Psychological Stress and Its Correlations to Patients with Acute Lymphedema After Breast Cancer SurgeryLi-Ping Ge, Lichen Tang, WenJia Zuo, et al.
Cell Research|January 3, 2024
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancerLi-Ping Ge, Xi Jin, Ding Ma, et al.
Breast Cancer Research and Treatment|September 25, 2020
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variationsYi-Zhou Jiang, Li-Ping Ge, Xi Jin, et al.
Cell Research|February 2, 2022
Comprehensive metabolomics expands precision medicine for triple-negative breast cancerYi Xiao, Ding Ma, Yun-Song Yang, et al.
Nature Chemistry|September 14, 2023
DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundanceQinqin Hu, Zongxuan Tong, Ayimukedisi Yalikong, et al.
Cancer Cell|December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrialLei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Theranostics|October 12, 2020
SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancerXi-Yu Liu, Wang Jiang, Ding Ma, et al.
Nature Communications|July 4, 2026
ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibitionLi-Ping Ge, Yu-Ling Xiao, Song-Yang Wu, et al.
Journal of Pharmacological Sciences|April 9, 2020
Finding a resveratrol analogue as potential anticancer agent with apoptosis and cycle arrestZhen-Hui Xin, Hui-Hui Yang, Yu-Han Gan, et al.
Breast Cancer (Dove Medical Press)|December 11, 2024
Psychological Stress and Its Correlations to Patients with Acute Lymphedema After Breast Cancer SurgeryLi-Ping Ge, Lichen Tang, WenJia Zuo, et al.
Cell Research|January 3, 2024
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancerLi-Ping Ge, Xi Jin, Ding Ma, et al.
Breast Cancer Research and Treatment|September 25, 2020
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variationsYi-Zhou Jiang, Li-Ping Ge, Xi Jin, et al.
Cell Research|February 2, 2022
Comprehensive metabolomics expands precision medicine for triple-negative breast cancerYi Xiao, Ding Ma, Yun-Song Yang, et al.
Nature Chemistry|September 14, 2023
DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundanceQinqin Hu, Zongxuan Tong, Ayimukedisi Yalikong, et al.
Cancer Cell|December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrialLei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Pageof 3